The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
you know when you talk about cardiovascular disease you have APO b as kind of a biomarker that's kind of a predictor of risk and something that people can easily run and understand where they're at is there anything equivalent to that for Alzheimer's or neurodegeneration so no I you know I would say that Alzheimer's is much more complicated in this regard and I don't think we have something that's as neat and tidy
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.